Aktienanalyse wird geladen …
INCY · NASDAQ · Research & Development · USA
123,89 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 5,14 Mrd. | 1,29 Mrd. | 6,41 $ | 200,7 Mio. | 2 Mio · 1 % | 11,8 Mio · 5,9 % | 92,8 % | 25 % | 6,62 $ | 1,24 $ | — |
| 2024 | 4,24 Mrd. | 32,62 Mio. | 0,15 $ | 210,53 Mio. | 2,1 Mio · 1 % | 17,5 Mio · 8,3 % | 92,6 % | 0,8 % | 1,12 $ | 1,26 $ | — |
| 2023 | 3,7 Mrd. | 597,6 Mio. | 2,65 $ | 225,93 Mio. | 1,7 Mio · 0,8 % | — | 93,1 % | 16,2 % | 1,99 $ | 0,96 $ | — |
| 2022 | 3,39 Mrd. | 340,66 Mio. | 1,52 $ | 223,96 Mio. | 1,5 Mio · 0,7 % | — | 93,9 % | 10 % | 3,98 $ | 0,84 $ | — |
| 2021 | 2,99 Mrd. | 948,58 Mio. | 4,27 $ | 222,07 Mio. | 1,5 Mio · 0,7 % | — | 94,9 % | 31,8 % | 2,56 $ | 0,82 $ | — |
| 2020 | 2,67 Mrd. | -295,7 Mio. | -1,36 $ | 218,07 Mio. | 1,4 Mio · 0,7 % | — | 95,1 % | -11,1 % | -1,43 $ | 0,82 $ | — |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Nettomarge |
|---|---|---|---|---|---|
| Q2 2026 | 1,67 Mrd. | 585,61 Mio. | 2,81 $ | 208,22 Mio. | 35 % |
| Q1 2026 | 1,27 Mrd. | 303,33 Mio. | 1,47 $ | 206,83 Mio. | 23,8 % |
| Q4 2025 | 1,51 Mrd. | 299,28 Mio. | 1,46 $ | 204,77 Mio. | 19,9 % |
| Q3 2025 | 1,37 Mrd. | 424,17 Mio. | 2,11 $ | 201,43 Mio. | 31,1 % |
| Q2 2025 | 1,22 Mrd. | 405 Mio. | 2,04 $ | 198,74 Mio. | 33,3 % |
| Q1 2025 | 1,05 Mrd. | 158,2 Mio. | 0,80 $ | 198,2 Mio. | 15 % |
| Q4 2024 | 1,18 Mrd. | 201,21 Mio. | 1,00 $ | — | 17,1 % |
| Q3 2024 | 1,14 Mrd. | 106,46 Mio. | 0,54 $ | 195,84 Mio. | 9,4 % |
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
INCY, MIRM Slip Into FDA’s Weekend Decision Date On Shared Rare-Disease Pill
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks?
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says
Incyte Corp. is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company’s current portfolio centers on hematology, oncology, and inflammation and autoimmunity, with products and programs aimed at treating cancers, blood disorders, and immune-mediated conditions. Incyte Corp. develops both small-molecule medicines and biologics, and its marketed therapies support patients with a range of specialty disease areas, including dermatology and rare hematologic disorders. The company also maintains a pipeline of clinical-stage candidates across its core therapeutic franchises, reflecting its role as a research-driven developer of targeted treatments. Headquartered in Wilmington, Delaware, Incyte Corp. serves healthcare markets in the United States and internationally through its commercial and development activities.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest INCY und jede andere Aktie unbegrenzt.